Prima BioMed Ltd. announced that Bradley J. Monk, MD, has joined the company's clinical advisory board to advise the company's development of CVac(TM) for the treatment of epithelial ovarian cancer. Dr. Monk is an active member of steering committees (SC) for the National Cancer Institute (NCI) and Gynecological Oncology Group (GOG).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3975 AUD | -0.62% | -6.47% | +15.22% |
05/06 | Immutep Completes Stock Offering | MT |
03/06 | Immutep, Merck Collaborate on Trial for Lung Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.22% | 337M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Bradley J. Monk to Join Prima Biomed's Clinical Advisory Board